RT Journal Article
T1 Chromium Exposure and Risk of Cardiovascular Disease in High Cardiovascular Risk Subjects　- Nested Case-Control Study in the Prevention With Mediterranean Diet (PREDIMED) Study.
A1 Gutiérrez-Bedmar, Mario
A1 Martínez-González, Miguel Ángel
A1 Muñoz-Bravo, Carlos
A1 Ruiz-Canela, Miguel
A1 Mariscal, Alberto
A1 Salas-Salvadó, Jordi
A1 Estruch, Ramón
A1 Corella, Dolores
A1 Arós, Fernando
A1 Fito, Monserrat
A1 Lapetra, José
A1 Serra-Majem, Lluís
A1 Pintó, Xavier
A1 Alonso-Gómez, Ángel
A1 Portoles, Olga
A1 Fiol, Miquel
A1 Bulló, Mónica
A1 Castañer, Olga
A1 Ros, Emilio
A1 Gómez-Gracia, Enrique
K1 Cardiovascular disease
K1 Chromium
K1 Diabetes
K1 PREDIMED
K1 Toenail biomarker
AB Epidemiological data on chromium (Cr) exposure and the risk of cardiovascular disease (CVD) are still limited. Toenail Cr level (TCL) provides a time-integrated measure reflecting long-term Cr exposure. We measured TCL to assess the hypothesis that long-term Cr exposure was inversely associated with incident CVD in a population at high risk for CVD.Methods and Results:The associations between TCL and CVD were evaluated in a case-control study nested within the "PREvención con DIeta MEDiterránea" (PREDIMED) trial. We randomly selected 147 of the 288 patients diagnosed with CVD during follow-up and matched them on age and sex to 271 controls. Instrumental neutron activation analysis was used to assess TCL. In-person interviews, medical record reviews, and validated questionnaires were used to assess covariates. The fully adjusted OR for the highest vs. lowest quartile of toenail Cr was 0.54 (95% CI: 0.26-1.14; Ptrend=0.189) for the nested case-control study. On stratification for diabetes mellitus (DM), OR was 1.37 (95% CI: 0.54-3.46; Ptrend=0.364) for the DM group, and 0.25 (95% CI: 0.08-0.80; Ptrend=0.030) for the non-DM group (P for interaction=0.078). The present findings, although not statistically significant, are consistent with previously reported inverse associations between TCL and CVD. These results, especially for non-DM patients, increase the limited epidemiological knowledge about the possible protective role of Cr against CVD. (Trial registration: www.controlled-trials.com; ISRCTN35739639.).
YR 2017
FD 2017-04-08
LK http://hdl.handle.net/10668/11072
UL http://hdl.handle.net/10668/11072
LA en
DS RISalud
RD Apr 10, 2025